[Form 4] Cytosorbents Corp Insider Trading Activity

Rhea-AI Filing Summary

Cytosorbents Corp (CTSO) reported that its Chief Executive Officer and director, Phillip P. Chan, acquired additional company stock in an open market transaction. On 11/18/2025, he purchased 100,000 shares of Common Stock at a price of $0.64 per share. Following this transaction, he beneficially owns 1,482,963 shares, reflecting both directly owned shares and various restricted stock units (RSUs).

The footnotes explain that his holdings include multiple RSU grants that either vest upon a "Change In Control" under the company’s 2014 Long-Term Incentive Plan or in equal parts on the first and second anniversaries of their grant dates, subject to continued service. His position also includes 1,113,363 shares of Common Stock owned outright.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Phillip P.

(Last) (First) (Middle)

C/O CYTOSORBENTS CORPORATION

305 COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytosorbents Corp [ CTSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		A		100,000(1)	A	$0.64	1,482,963(2)(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 reflects an open market purchase made by the reporting person.

2. Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

3. (continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof;

4. (continued from footnote 3) (iv) 105,600 RSUs which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and (v) 1,113,363 shares of Common Stock owned by the Reporting Person.

	/s/ Phillip P. Chan	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cytosorbents Corp (CTSO) report?

Cytosorbents Corp reported that its CEO and director, Phillip P. Chan, made an open market purchase of 100,000 shares of Common Stock on 11/18/2025 at $0.64 per share.

How many Cytosorbents (CTSO) shares does the CEO beneficially own after this transaction?

After the reported purchase, Phillip P. Chan beneficially owns 1,482,963 shares of Cytosorbents Common Stock, including both directly owned shares and RSUs described in the footnotes.

What portion of Cytosorbents (CTSO) CEO holdings are outright shares vs. RSUs?

The holdings include 1,113,363 shares of Common Stock owned by the reporting person, plus multiple restricted stock unit (RSU) grants that will settle into shares upon vesting or a specified event.

How do the Cytosorbents (CTSO) RSUs held by the CEO vest?

Certain RSUs vest upon a "Change In Control" of the company under its 2014 Long-Term Incentive Plan. Other RSUs vest in equal parts on the first and second anniversaries of their grant dates, subject to continued service, and then settle into shares of Common Stock.

Which RSU grants for Cytosorbents (CTSO) are subject to a Change In Control condition?

RSUs granted on April 8, 2015, June 7, 2016, February 24, 2017, and March 15, 2018 will be settled into shares of Common Stock upon vesting that occurs on a "Change In Control" as defined in the company’s 2014 Long-Term Incentive Plan.

What are the key recent RSU grants for the Cytosorbents (CTSO) CEO?

The filing notes 96,000 RSUs granted on April 2, 2024, of which 48,000 remain unvested, and an additional 105,600 RSUs that vest in equal parts at the first and second anniversaries of the grant date, subject to continued service.